Clinical trial
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate…
NCT00183937 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00183937 |
|---|---|
| Title | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer |
| Official title | A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | PS 341, Docetaxel |
| Enrollment | 15 |
| Start date | Apr 30, 2005 |
| Primary completion | Oct 23, 2010 |
| Completion | Jun 11, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | May 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: